Retinal and choroidal thickness changes after single anti-vegf injection in neovascular age-related macular degeneration: Ranibizumab vs bevacizumab

European Journal of Ophthalmology

Volumn 24, Issue 6, 2014, Pages 904-910

  Sizmaz, Selcuk ^a   Kucukerdonmez, Cem ^b   Kal, Ali ^c   Pinarci, Eylem Yaman ^c   Canan, Handan ^c   Yilmaz, Gürsel ^c  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b IZMIR UNIVERSITY   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Choroidal thickness; Optical coherence tomography; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CHOROIDAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; VERY ELDERLY; VISUAL SYSTEM PARAMETERS; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CHOROID; COMPARATIVE STUDY; FOURIER ANALYSIS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETROSPECTIVE STUDY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; FEMALE; FOURIER ANALYSIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84907814046     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000478     Document Type: Article

References (42)

1. Lally DR, Gerstenblith AT, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2012;23:182-8.
2. Zampros I, Praidou A, Brazitikos P, Ekonokidis P, Androudi S. Antivascular endothelial growth factor agents for neo-vascular age-related macular degeneration. J Ophthalmol 2012;2012:319728.
3. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013;156:23-28.
4. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114: 1868-75.
6. Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina 2010;30: 1390-9.
7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neo-vascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
8. Bashshur ZF, Haddad ZA, Schakal A, Jaafar R F, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-56.
9. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007;143:510-2.
10. Martin D F, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevaci-zumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
11. Comparison of Age-related macular degeneration Treatment Trials (CATT) Research Group. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age related macular degeneration: two year results. Ophthalmology 2012;119:1388-98.
12. Chakravarthy U, Harding S P, Rogers CA, et al; IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
13. Manjunath V, Goren J, Fujimoto JG, Duker JS. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography. Am J Ophthalmol 2011;152:663-8.
14. Wood A, Binns A, Margrain T, et al. Retinal and choroidal thickness in early age-related macular degeneration. Am J Ophthalmol 2011;152:1030-8.
15. ®) in neovascular age-related macular degeneration. Acta Ophthalmol 2010;88: 641-5.
16. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116: 1755-61.
17. Manjunath V, Taha M, Fujimoto JG, Duker JS. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol 2010;150:325-9.
18. Branchini L, Regatieri CV, Flores-Moreno I, Baumann B, Fujimoto JG, Duker JS. Reproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems. Ophthalmology 2012;119: 119-23.
19. Fujiwara T, Imamura Y, Margolis R, Slakter JS, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol 2009;148: 445-50.
20. Spaide R F, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography [erratum 2009; 148: 325]. Am J Ophthalmol 2008;146:496-500.
21. Ikuno Y, Tano Y. Retinal and choroidal biometry in highly myopic eyes with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2009;50:3876-80.
22. Yeoh J, Rahman W, Chen F, et al. Choroidal imaging in inherited retinal disease using the technique of enhanced depth imaging optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2010;248:1719-28.
23. Spaide R F. Age-related choroidal atrophy. Am J Ophthalmol 2009;147:801-10.
24. Imamura Y, Fujiwara T, Margolis R, Spaide R F. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-73.
25. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide R F. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117:1792-9.
26. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina 2011;31:510-7.
27. Hirooka K, Tenkumo K, Fujiwara A, Baba T, Sato S, Shiraga F. Evaluation of peripapillary choroidal thickness in patients with normal-tension glaucoma. BMC Ophthalmol 2012;12:29.
28. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina 2011;31:332-5.
29. Tan CS, Ouyang Y, Ruiz H, Sadda SR. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Oph-thalmol Vis Sci 2012;53:261-6.
30. Fitzgerald ME, Wildsoet C F, Reiner A. Temporal relationship of choroidal blood flow and thickness changes during recovery from form deprivation myopia in chicks. Exp Eye Res 2002;74:561-70.
31. ®). Acta Ophthalmol 2013;91:183-8.
32. Sogawa K, Nagaoka T, Takahashi A, et al. Relationship between choroidal thickness and choroidal circulation in healthy young subjects. Am J Ophthalmol 2012;153: 1129-32.
33. Harris A, Chung HS, Ciulla TA, Kagemann L. Progress in measurement of ocular blood flow and relevance to our understanding of glaucoma and age-related macular degeneration. Prog Retin Eye Res 1999;18:669-87.
34. Ciulla TA, Harris A, Chung HS, et al. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexu-dative age-related macular degeneration. Am J Ophthalmol 1999;128:75-80.
35. Chung SE, Kang SW, Lee JH, Kim YT. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 2011;118:840-5.
36. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-7.
37. Ng EW, Adamis A P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68.
38. Storkebaum E, Carmeliet P. VEGF: a critical player in neuro-degeneration. J Clin Invest 2004;113:14-8.
39. Tilton RG, Chang KC, LeJeune WS, Stephan CC, Brock TA, Williamson JR. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999;40:689-96.
40. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 2012;6:837-44.
41. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovas-cular age-related macular degeneration: 12-month results. Ophthalmology 2012;119:1621-7.
42. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol 2009;147:811-5.